Drug Approval PotentialWith potential U.S. approval of treosulfan, Medexus could see an increase in value, potentially adding significant additional value to the stock.
Financial HealthStrong cash generation, alongside the strategic repayment of convertible debentures, underscores the company's solid financial management and commitment to reducing debt.
Growth OpportunityThe completion of the data collection phase for treosulfan's FDA resubmission by partner medac could act as a positive catalyst, highlighting a substantial growth opportunity for the company.